New stock news: English Silicon Intelligence successfully listed on the Hong Kong stock market and obtained approval from the China Securities Regulatory Commission.

On November 10, the China Securities Regulatory Commission issued the "Notice on the Overseas Issuance and Listing Record of InSilico Medicine Cayman TopCo (EpsilonAI)". The company plans to issue no more than 70,890,500 overseas listed common shares and list on the Hong Kong Stock Exchange. On June 27, EpsilonAI submitted its listing application to the Hong Kong Stock Exchange, with Morgan Stanley and CICC as the joint sponsors. According to the prospectus, EpsilonAI is an AI biotech company that provides end-to-end efficient solutions in the pipeline development process. Its business covers the United States, Greater China, Canada, and the Middle East. In 2019, the company established its headquarters in Hong Kong, with a team composed of disease modeling, target discovery scientists, and generative AI engineers led by a CEO based in Hong Kong. The company's generative AI platform can rapidly and effectively advance the fully autonomous design and development of AIDD pipeline primarily composed of new candidate drugs. The company has partnerships with Fosun and Sanofi.